Physician profile
Alla Gruman
NPI 1629087911
$7,432.37
in general payments reported to CMS, 2019-2025
43 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $934 · 2021: $1,084 · 2022: $843 · 2023: $1,147 · 2024: $1,199 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.57 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $761.00 | 2019-2025 | Ilumya |
| Genzyme Corporation | $676.60 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $593.69 | 2019-2023 | Dupixent |
| Janssen Biotech, INC. | $546.78 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $529.76 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $445.11 | 2019-2025 | |
| Lilly USA, LLC | $434.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $339.90 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $336.03 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $326.38 | 2019-2024 | Siliq |
| Pfizer INC. | $316.10 | 2019-2025 | |
| Incyte Corporation | $207.75 | 2021-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.43 | 2022-2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $162.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.48 | 2022-2025 | Sotyktu |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $139.44 | 2019-2022 | |
| Galderma Laboratories, L.P. | $128.30 | 2019-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $111.14 | 2023-2025 | Zoryve |
| Amgen INC. | $99.60 | 2020-2025 | Otezla, Otezla |
| Biofrontera INC. | $79.82 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $68.85 | 2019-2024 | Xolair |
| Dermavant Sciences, INC. | $68.43 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $66.99 | 2024-2025 | Xtrac |
| Almirall LLC | $63.31 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $61.21 | 2020 | |
| Convatec INC. | $52.88 | 2024-2025 | |
| Journey Medical Corporation | $44.55 | 2020-2021 | |
| Elekta, INC. | $41.34 | 2024 | Elekta Medical Linear Accelerator |
| Krystal Biotech INC | $39.11 | 2023 | Vyjuvek |
| Dermira, INC. | $38.11 | 2019-2020 | |
| Organogenesis INC. | $36.86 | 2025 | Via Matrix |
| Helsinn Therapeutics (U.S.), INC. | $36.19 | 2021-2023 | Valchlor |
| Aclaris Therapeutics, INC. | $33.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.17 | 2019 | |
| Mimedx Group, INC. | $32.43 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $31.29 | 2019 | |
| Verrica Pharmaceuticals INC. | $26.92 | 2024 | Ycanth |
| Encore Dermatology INC. | $22.47 | 2020 | |
| Celgene Corporation | $20.54 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.30 | 2024 | Nuzyra |
| Kyowa Kirin, INC. | $16.76 | 2020 | |
| Merz North America, INC. | $16.03 | 2021 | |
| Nabriva Therapeutics, Plc | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Gruman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.